People · Operator
Named in public records as an officer, director or promoter · active 2009–2016 · Other, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Myoscience, Inc | — | Other | Series B | $122.6M | $83.1M | 2010 |
| Eyegate Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $72.9M | $92.5M | 2009 |
| Spectra Analysis Instruments, Inc. | — | Other Technology | Seed | $2.9M | $46.1M | 2013 |
Thomas E. Hancock at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas E. Hancock on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Ferrari | 1 | 15 |
| Robert Grant | 1 | 12 |
| Anthony Lando | 1 | 6 |
| Richard M. Ferrari | 1 | 5 |
| Praveen Tyle | 1 | 5 |
| Brian Farley | 1 | 5 |
| Eric Daniels | 1 | 4 |
| Clint Carnell | 1 | 4 |
| Cary . Vance | 1 | 4 |
| Jan Pensaert | 1 | 3 |
| David Hollander | 1 | 3 |
| Rudi Marien | 1 | 3 |
| Steven Boyd | 1 | 3 |
| Jon Serbousek | 1 | 3 |
| Thomas Weldon | 1 | 3 |
| Peter Greenleaf | 1 | 3 |
| Sarah Romano | 1 | 3 |
| Bernard Malfroy-Camine | 1 | 2 |
| Stephen From | 1 | 2 |
| Paul Chaney | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.